000157814 001__ 157814
000157814 005__ 20240305154120.0
000157814 0247_ $$2doi$$a10.1212/WNL.0000000000011790
000157814 0247_ $$2pmid$$apmid:33653897
000157814 0247_ $$2ISSN$$a0028-3878
000157814 0247_ $$2ISSN$$a1526-632X
000157814 0247_ $$2altmetric$$aaltmetric:101224786
000157814 037__ $$aDZNE-2021-01271
000157814 041__ $$aEnglish
000157814 082__ $$a610
000157814 1001_ $$aRotta, Johanna$$b0
000157814 245__ $$aDetection of Cerebral Microbleeds With Venous Connection at 7-Tesla MRI.
000157814 260__ $$a[S.l.]$$bOvid$$c2021
000157814 3367_ $$2DRIVER$$aarticle
000157814 3367_ $$2DataCite$$aOutput Types/Journal article
000157814 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1709649657_29110
000157814 3367_ $$2BibTeX$$aARTICLE
000157814 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157814 3367_ $$00$$2EndNote$$aJournal Article
000157814 520__ $$aCerebral microbleeds (MBs) are a common finding in patients with cerebral small vessel disease (CSVD) and Alzheimer disease as well as in healthy elderly people, but their pathophysiology remains unclear. To investigate a possible role of veins in the development of MBs, we performed an exploratory study, assessing in vivo presence of MBs with a direct connection to a vein.7-Tesla (7T) MRI was conducted and MBs were counted on quantitative susceptibility mapping (QSM). A submillimeter resolution QSM-based venogram allowed identification of MBs with a direct spatial connection to a vein.A total of 51 people (mean age [SD] 70.5 [8.6] years, 37% female) participated in the study: 20 had CSVD (cerebral amyloid angiopathy [CAA] with strictly lobar MBs [n = 8], hypertensive arteriopathy [HA] with strictly deep MBs [n = 5], or mixed lobar and deep MBs [n = 7], 72.4 [6.1] years, 30% female) and 31 were healthy controls (69.4 [9.9] years, 42% female). In our cohort, we counted a total of 96 MBs with a venous connection, representing 14% of all detected MBs on 7T QSM. Most venous MBs (86%, n = 83) were observed in lobar locations and all of these were cortical. Patients with CAA showed the highest ratio of venous to total MBs (19%) (HA = 9%, mixed = 18%, controls = 5%).Our findings establish a link between cerebral MBs and the venous vasculature, pointing towards a possible contribution of veins to CSVD in general and to CAA in particular. Pathologic studies are needed to confirm our observations.
000157814 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000157814 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000157814 650_2 $$2MeSH$$aAged
000157814 650_2 $$2MeSH$$aCerebral Hemorrhage: diagnostic imaging
000157814 650_2 $$2MeSH$$aCerebral Hemorrhage: etiology
000157814 650_2 $$2MeSH$$aCerebral Hemorrhage: pathology
000157814 650_2 $$2MeSH$$aCerebral Small Vessel Diseases: complications
000157814 650_2 $$2MeSH$$aCerebral Small Vessel Diseases: pathology
000157814 650_2 $$2MeSH$$aFemale
000157814 650_2 $$2MeSH$$aHumans
000157814 650_2 $$2MeSH$$aImage Interpretation, Computer-Assisted
000157814 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000157814 650_2 $$2MeSH$$aMale
000157814 650_2 $$2MeSH$$aMiddle Aged
000157814 650_2 $$2MeSH$$aNeuroimaging: methods
000157814 650_2 $$2MeSH$$aVeins: diagnostic imaging
000157814 650_2 $$2MeSH$$aVeins: pathology
000157814 7001_ $$0P:(DE-2719)9000985$$aPerosa, Valentina$$b1$$udzne
000157814 7001_ $$0P:(DE-2719)2812398$$aYakupov, Renat$$b2$$udzne
000157814 7001_ $$00000-0001-6997-9059$$aKuijf, Hugo J$$b3
000157814 7001_ $$0P:(DE-2719)9000986$$aSchreiber, Frank$$b4$$udzne
000157814 7001_ $$0P:(DE-2719)2811611$$aDobisch, Laura$$b5$$udzne
000157814 7001_ $$0P:(DE-2719)2811736$$aOltmer, Jan$$b6$$udzne
000157814 7001_ $$0P:(DE-2719)2812914$$aAssmann, Anne$$b7$$udzne
000157814 7001_ $$0P:(DE-2719)2810706$$aSpeck, Oliver$$b8$$udzne
000157814 7001_ $$0P:(DE-2719)2260426$$aHeinze, Hans-Jochen$$b9$$udzne
000157814 7001_ $$0P:(DE-2719)2810751$$aAcosta-Cabronero, Julio$$b10$$udzne
000157814 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b11$$udzne
000157814 7001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b12$$eLast author$$udzne
000157814 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000011790$$gVol. 96, no. 16, p. e2048 - e2057$$n16$$pe2048 - e2057$$tNeurology$$v96$$x1526-632X$$y2021
000157814 909CO $$ooai:pub.dzne.de:157814$$pVDB
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000985$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812398$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000986$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811611$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811736$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812914$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810706$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2260426$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810751$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000157814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000157814 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000157814 9141_ $$y2021
000157814 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000157814 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000157814 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000157814 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2022-11-12$$wger
000157814 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2021$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000157814 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEUROLOGY : 2021$$d2022-11-12
000157814 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x0
000157814 9201_ $$0I:(DE-2719)1310010$$kAG Schreiber$$lMixed Cerebral Pathologies and Cognitive Aging$$x1
000157814 9201_ $$0I:(DE-2719)1340009$$kAG Speck$$lLinking imaging projects iNET$$x2
000157814 9201_ $$0I:(DE-2719)1310002$$kAG Wolbers$$lAging, Cognition and Technology$$x3
000157814 9201_ $$0I:(DE-2719)1310001$$kAG Nestor$$lCognitive Neurology and Neurodegeneration$$x4
000157814 9201_ $$0I:(DE-2719)7000000$$kU Clinical Researchers - Magdeburg$$lU Clinical Researchers - Magdeburg$$x5
000157814 980__ $$ajournal
000157814 980__ $$aVDB
000157814 980__ $$aI:(DE-2719)5000006
000157814 980__ $$aI:(DE-2719)1310010
000157814 980__ $$aI:(DE-2719)1340009
000157814 980__ $$aI:(DE-2719)1310002
000157814 980__ $$aI:(DE-2719)1310001
000157814 980__ $$aI:(DE-2719)7000000
000157814 980__ $$aUNRESTRICTED